Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSA… Read more
Antibe Therapeutics Inc - Asset Resilience Ratio
Antibe Therapeutics Inc (ATBPF) has an Asset Resilience Ratio of 24.07% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Antibe Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Antibe Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $13.57 Million | 24.07% |
| Total Liquid Assets | $13.57 Million | 24.07% |
Asset Resilience Insights
- Good Liquidity Position: Antibe Therapeutics Inc maintains a healthy 24.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Antibe Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Antibe Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Antibe Therapeutics Inc (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Antibe Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-03-31 | 45.54% | $32.14 Million | $70.56 Million | +23.11pp |
| 2022-03-31 | 22.43% | $20.00 Million | $89.16 Million | +22.40pp |
| 2021-03-31 | 0.03% | $25.00K | $81.74 Million | -0.15pp |
| 2020-03-31 | 0.18% | $25.00K | $13.84 Million | +0.01pp |
| 2019-03-31 | 0.17% | $25.00K | $14.82 Million | -0.03pp |
| 2018-03-31 | 0.20% | $25.00K | $12.49 Million | -0.03pp |
| 2017-03-31 | 0.23% | $25.00K | $10.73 Million | -0.02pp |
| 2016-03-31 | 0.26% | $25.00K | $9.74 Million | -14.68pp |
| 2014-03-31 | 14.94% | $650.00K | $4.35 Million | -- |